SecBot SecBot
8-K ·Filed Aug 6, 2026

LGND

LIGAND PHARMACEUTICALS INC
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0000886163-26-000041
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat and guidance raise confirm accelerating royalty momentum, while the XOMA close and $700M deployable capital signal a larger, more diversified platform. Monitor Q3 for initial XOMA contribution and any further royalty acquisitions; the $524.34 warrant strike caps near-term dilution risk.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

LGND drug pipeline →

Ersodetug

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If the full upLIFT results (expected mid-December 2026) remain positive, Rezolute could file a Biologics License Application (BLA) for tumor hyperinsulinism in 2027. The congenital HI path is less clear after the sunRIZE miss, though the FDA has recommended a pre-BLA meeting. Analyst projections from 2025 suggested a potential market launch in 2027 for at least one indication.
Next catalyst
None dated

What to watchThe next hard catalyst for ersodetug is the full topline results from the Phase 3 upLIFT study in tumor HI, expected by mid-December 2026. Positive results would support a BLA filing for tumor HI, while the congenital HI path remains uncertain after the sunRIZE miss. For LGND holders, this is a minor portfolio contributor; for RZLT holders, it is the primary value driver.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$300.14
T+0 close · Aug 6, 2026 · via day close
Latest settled
+7.53%
T+60 · $322.75
Vs SPY
+9.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $300.14entry
  2. T+1 · 3mo ago −2.33%α −2.94% · $293.15
  3. T+5 · 3mo ago −3.77%α −4.98% · $288.82
  4. T+20 · 3mo ago −3.46%α −4.06% · $289.74
  5. T+60 · 18d ago +7.53%α +9.20% · $322.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ligand reported Q2 2026 adjusted EPS of $2.37, a 20.3% beat vs consensus of $1.97, driven by 32% YoY royalty revenue growth to $48.0M. The company raised the low end of its 2026 adjusted EPS guidance to $9.00-$9.50 (from $8.50-$9.50) and closed the XOMA Royalty acquisition on July 14, 2026, adding over 120 assets. The strong beat, guidance raise, and transformative acquisition close are clearly positive, but the $700M convertible debt issuance and share repurchase at ~$262 introduce modest dilution and capital structure complexity.

Key Financial Metrics

EPS
$2.37
est $1.97 · +20.3%
Revenue
$63.7M
est $61.3M · +3.9% · +33.7% YoY
Rating
strong beat
Guidance
$270M-$310M
raised

Key Facts

  • Q2 2026 adjusted EPS of $2.37 beat consensus of $1.97 by 20.3%
  • Q2 2026 total revenue of $63.7M beat consensus of $61.3M by 3.9%
  • Royalty revenue grew 32% YoY to $48.0M, driven by Filspari, Zelsuvmi, and Ohtuvayre
  • Raised low end of 2026 adjusted EPS guidance to $9.00-$9.50 (from $8.50-$9.50); revenue guidance unchanged at $270M-$310M
  • Closed XOMA Royalty acquisition on July 14, 2026, adding >120 assets for $39.00/share plus CVR
  • Completed $700M 0.00% convertible note offering due 2031; used ~$60M to repurchase 228,859 shares at ~$262/share
  • Cash, cash equivalents, and short-term investments were $1.36B at June 30, 2026, up from $733.5M at Dec 31, 2025
  • Filspari (Travere) Q2 net sales grew 96% YoY to $141M, driven by FSGS launch and IgAN growth

Financial Impact

Adjusted EPS beat consensus by $0.40 (20.3%); revenue beat by $2.4M (3.9%); guidance raised by $0.50 at low end

epsrevenueroyalty revenueguidance

Risk Factors

  • Integration risk from XOMA acquisition; potential for higher-than-expected operating costs
  • Dependence on partner commercial execution (Filspari, Ohtuvayre, Capvaxive) for royalty growth
  • Convertible debt ($1.13B net) increases leverage; dilution risk if stock exceeds $524.34
  • Captisol sales declining (down 4% YoY in Q2) and subject to customer order timing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000886163-26-000041
Document: lgnd-20260806.htm0000886163-26-000041
Document: 0000886163-26-000041-index-headers.html0000886163-26-000041
Document: 0000886163-26-000041-index.html0000886163-26-000041
Document: 0000886163-26-000041.txt0000886163-26-000041
8-K Data (Synthetic)0000886163-26-000041

US Market Status

Market Closed · Opens Wed (9h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026